glp-1 novo Novo's Wegovy becomes first drug approved for MASH Novo Nordisk sues Hims for

David Ludwig (Harvard, Boston Childrens Hospital) and journalist Gary Taubes explore the science behind GLP-1s, their impact on insulin, weight loss, and chronic disease, and where dietary strategies like low carb or ketogenic therapy fit in

Wang G, Gao S, Su N, Xu J, Fu D

In primary mouse chondrocytes, treatment with liraglutide reduced the mRNA expression of iNOS, MMP-13 and ADAMTS5 , thus leading to reduced secretion of a battery of inflammatory markers such as NO, prostaglandin E 2 , and IL-6 [17]

In June 2025, MBX Biosciences announced that it has submitted an IND application to the FDA for MBX 4291, a long-acting GLP-1/GIP receptor co-agonist prodrug targeting obesity, which received regulatory clearance in July

FeelGood's published Terms explicitly state that approval is not guaranteed

Some platforms prioritize rapid access over thorough evaluation